Subscribe
pfizer-logo-slider
pio3 / shutterstock.com
18 October 2016Americas

Pfizer to launch second-ever biosimilar in the US

Pfizer announced yesterday that it will launch a biosimilar of one of Johnson & Johnson’s (J&J) best-selling drugs, Remicade (infliximab), which brought in a total of $9.2 billion in revenue last year.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Janssen Remicade patent invalidated in Massachusetts
18 August 2016   The US District Court for the District of Massachusetts has issued a ruling on a summary judgment motion filed by Celltrion Healthcare and Hospira, invalidating a Janssen patent related to Remicade.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Janssen Remicade patent invalidated in Massachusetts
18 August 2016   The US District Court for the District of Massachusetts has issued a ruling on a summary judgment motion filed by Celltrion Healthcare and Hospira, invalidating a Janssen patent related to Remicade.

More on this story

Americas
Janssen Remicade patent invalidated in Massachusetts
18 August 2016   The US District Court for the District of Massachusetts has issued a ruling on a summary judgment motion filed by Celltrion Healthcare and Hospira, invalidating a Janssen patent related to Remicade.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers